CN1236775C - 用于降低眼高压的组合物和方法 - Google Patents

用于降低眼高压的组合物和方法 Download PDF

Info

Publication number
CN1236775C
CN1236775C CNB988030195A CN98803019A CN1236775C CN 1236775 C CN1236775 C CN 1236775C CN B988030195 A CNB988030195 A CN B988030195A CN 98803019 A CN98803019 A CN 98803019A CN 1236775 C CN1236775 C CN 1236775C
Authority
CN
China
Prior art keywords
composition
weight percent
preservative
prostaglandin
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988030195A
Other languages
English (en)
Chinese (zh)
Other versions
CN1249687A (zh
Inventor
K·W·利德
严绍峰
M·索乌
R·F·皮考克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1236775(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1249687A publication Critical patent/CN1249687A/zh
Application granted granted Critical
Publication of CN1236775C publication Critical patent/CN1236775C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
CNB988030195A 1997-03-17 1998-03-13 用于降低眼高压的组合物和方法 Expired - Fee Related CN1236775C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17
US08/819,221 1997-03-17

Publications (2)

Publication Number Publication Date
CN1249687A CN1249687A (zh) 2000-04-05
CN1236775C true CN1236775C (zh) 2006-01-18

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988030195A Expired - Fee Related CN1236775C (zh) 1997-03-17 1998-03-13 用于降低眼高压的组合物和方法

Country Status (32)

Country Link
EP (1) EP0969846B2 (enExample)
JP (2) JP4920124B2 (enExample)
KR (1) KR100555818B1 (enExample)
CN (1) CN1236775C (enExample)
AR (2) AR002194A1 (enExample)
AT (1) ATE257385T1 (enExample)
AU (1) AU738781B2 (enExample)
BR (2) BRPI9816218B1 (enExample)
CA (1) CA2280089C (enExample)
CL (1) CL2009001870A1 (enExample)
CO (1) CO4940427A1 (enExample)
CY (1) CY2526B1 (enExample)
CZ (1) CZ299833B6 (enExample)
DE (1) DE69820997T3 (enExample)
DK (1) DK0969846T4 (enExample)
EE (1) EE04091B1 (enExample)
ES (1) ES2214706T5 (enExample)
HU (1) HU228896B1 (enExample)
ID (1) ID22389A (enExample)
IL (1) IL131041A0 (enExample)
MY (1) MY122237A (enExample)
NO (1) NO327713B1 (enExample)
NZ (1) NZ337322A (enExample)
PE (1) PE61899A1 (enExample)
PL (1) PL197509B1 (enExample)
PT (1) PT969846E (enExample)
RU (1) RU2197970C2 (enExample)
SI (1) SI0969846T2 (enExample)
TW (1) TW527187B (enExample)
UA (1) UA63938C2 (enExample)
WO (1) WO1998041208A1 (enExample)
ZA (1) ZA982188B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) * 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
DK1321144T3 (da) * 2000-09-13 2011-03-07 Santen Pharmaceutical Co Ltd Øjendråber
WO2002045748A1 (en) * 2000-12-05 2002-06-13 Sankyo Company, Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
ES2331890T3 (es) * 2004-03-18 2010-01-19 R-Tech Ueno, Ltd. Composicion acuosa que comprende un derivado de tiazol.
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
EP1916002B1 (en) * 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
JP5275214B2 (ja) * 2006-03-17 2013-08-28 ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド 酸化に不安定な成分を含む眼科用安定組成物
AU2007313684A1 (en) * 2006-10-31 2008-05-08 Alcon Research, Ltd. PAI-1 binding modulators for the treatment of ocular disorders
JPWO2008096804A1 (ja) * 2007-02-07 2010-05-27 テイカ製薬株式会社 ラタノプロスト含有点眼剤
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
CN101820917B (zh) * 2007-10-08 2013-01-02 佛维雅制药股份有限公司 水性眼科配制剂
AU2009225931B9 (en) * 2008-03-17 2014-04-03 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
JP2014510709A (ja) * 2011-04-12 2014-05-01 株式会社アールテック・ウエノ 眼科用水性組成物
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
HUE057140T2 (hu) 2011-12-07 2022-04-28 Allergan Inc Hatásos lipidszállítás humán könny-filmhez sóérzékeny emulziórendszer alkalmazásával
RU2697844C9 (ru) 2014-11-25 2019-10-01 Аллерган, Инк. Стабилизированные композиции для офтальмологического применения, содержащие омега-3-кислоты
AU2019343188A1 (en) * 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
BR112021020425A2 (pt) 2019-04-12 2021-12-14 Ecolab Usa Inc Composições de limpeza multiuso concentrada e pronta para uso, e, métodos para limpar uma superfície e de fabricação da composição de limpeza multiuso

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458587B1 (en) * 1990-05-22 1993-07-14 R-Tech Ueno Ltd. Synergistic combination for ophthalmic use
IE920397A1 (en) * 1991-02-07 1992-08-12 Allergan Inc 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
JP2742333B2 (ja) * 1994-05-06 1998-04-22 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるビタミンｅトコフェリル誘導体の使用
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
CL2009001870A1 (es) 2010-01-22
DE69820997T3 (de) 2011-10-06
RU2197970C2 (ru) 2003-02-10
NZ337322A (en) 2001-05-25
BR9808016A (pt) 2000-03-08
PE61899A1 (es) 1999-06-30
SI0969846T1 (en) 2004-06-30
CY2526B1 (en) 2006-02-08
SI0969846T2 (sl) 2010-12-31
EE9900410A (et) 2000-04-17
JP2010043110A (ja) 2010-02-25
ID22389A (id) 1999-10-07
EP0969846B2 (en) 2010-08-25
KR100555818B1 (ko) 2006-03-03
ATE257385T1 (de) 2004-01-15
NO327713B1 (no) 2009-09-14
KR20000076330A (ko) 2000-12-26
CO4940427A1 (es) 2000-07-24
WO1998041208A1 (en) 1998-09-24
DK0969846T4 (da) 2010-12-20
JP4920124B2 (ja) 2012-04-18
PL197509B1 (pl) 2008-04-30
CA2280089C (en) 2009-03-03
HU228896B1 (en) 2013-06-28
HK1026841A1 (en) 2000-12-29
BRPI9816218B1 (pt) 2016-04-12
JP2001515502A (ja) 2001-09-18
DE69820997T2 (de) 2004-12-09
TW527187B (en) 2003-04-11
DE69820997D1 (de) 2004-02-12
HUP0002194A2 (hu) 2000-12-28
ES2214706T5 (es) 2011-02-02
HUP0002194A3 (en) 2012-08-28
EP0969846A1 (en) 2000-01-12
CZ299833B6 (cs) 2008-12-10
AU738781B2 (en) 2001-09-27
ZA982188B (en) 1998-09-17
AU7035398A (en) 1998-10-12
MY122237A (en) 2006-04-29
EP0969846B1 (en) 2004-01-07
NO994481D0 (no) 1999-09-16
AR002194A1 (es) 1998-01-07
CN1249687A (zh) 2000-04-05
IL131041A0 (en) 2001-01-28
ES2214706T3 (es) 2004-09-16
NO994481L (no) 1999-09-16
PL335168A1 (en) 2000-04-10
PT969846E (pt) 2004-05-31
AR011192A1 (es) 2000-08-02
CA2280089A1 (en) 1998-09-24
UA63938C2 (uk) 2004-02-16
DK0969846T3 (da) 2004-04-13
EE04091B1 (et) 2003-08-15
CZ325799A3 (cs) 2000-01-12

Similar Documents

Publication Publication Date Title
CN1236775C (zh) 用于降低眼高压的组合物和方法
US6770675B2 (en) Compositions and methods for reducing ocular hypertension
CN1146423C (zh) 前列腺素产品
CN1313447C (zh) 用于降低眼内压的8－氮杂前列腺素类似物
CN1094614A (zh) 眼用或鼻用抗过敏组合物
JP2017132790A (ja) シクロスポリン組成物
US20070238732A1 (en) Brimonidine and timolol compositions
WO2005025539A1 (ja) コンタクトレンズ用眼科用組成物
JP2010540446A (ja) シクロスポリン組成物
CN1658888A (zh) 季铵环糊精化合物
JP2002316926A (ja) コンタクトレンズ用眼科用組成物及び眼刺激性の緩和方法
JP2009256281A (ja) イソプロピルウノプロストン含有点眼剤組成物
HK1026841B (en) Compositions and methods for reducing ocular hypertension
WO2003020283A2 (en) Method for treating diabetic retinopathy
HK1057478A (en) Ophthalmic solution

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060118

Termination date: 20160313

CF01 Termination of patent right due to non-payment of annual fee